Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Stefanie Jänsch"'
Publikováno v:
Frontiers in Veterinary Science, Vol 7 (2020)
Being a model for endangered wild felids, cryopreservation protocols for domestic cat oocytes are under continuous development. Immature vitrified oocytes (VOs) are a valuable resource for fertility preservation programs, but they often degenerate af
Externí odkaz:
https://doaj.org/article/949c1920a93e42d0850d50875c4139cd
Autor:
Lorena Fernandez-Gonzalez, Valeria Kozhevnikova, Eugeny Brusentsev, Stefanie Jänsch, Sergei Amstislavsky, Katarina Jewgenow
Publikováno v:
Animals, Vol 11, Iss 7, p 1909 (2021)
Embryo production is a routine procedure in several species. However, in felids, the effectiveness of this approach is far behind that in the majority of laboratory species. The development of a suitable environment starts with the proper composition
Externí odkaz:
https://doaj.org/article/6fb20d5c113c40918739e71168845ad1
Autor:
Katarina Jewgenow, Kim Skalborg Simonsen, Ditte-Mari Sandgreen, Jennifer Zahmel, Martina Colombo, Stefanie Jänsch
Publikováno v:
Cryobiology. 98:146-151
The African lion is an excellent model species for the highly endangered Asiatic lion. African lions reproduce well in zoos, leading to the fact that occasionally ovaries and testis are available for in-vitro experiments. We previously performed in-v
Publikováno v:
Theriogenology. 126
The outcome of in-vitro-maturation and in-vitro-fertilization of feline oocytes depends on the selection of high quality oocytes, and is often restricted to morphological criteria. The aim of this study was to test whether the Brilliant cresyl blue (
Publikováno v:
Cryobiology. 97:263
Autor:
Lisa Schneider, Jacqueline Schneider, Nadine Gollinge, Stefanie Jänsch, Burghardt Wittig, Kerstin Kapp, Christiane Kleuss, Matthias Schroff
Publikováno v:
Immunity, Inflammation and Disease
Introduction DNA‐based TLR9 agonists are potent activators of the immune system. ProMune® and dSLIM® belong to different families of TLR9 agonists and both have been established as cancer immunotherapeutics in clinical proof‐of‐concept studie